Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Selumetinib in KRASm NSCLC
NCT02450656Phase 2Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib, selumetinib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), gastrointestinal neoplasms, sponsored by Netherlands Cancer Institute. Status: unknown.
02
Drugs
afatinibselumetinib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)gastrointestinal neoplasms
Beyond the preview
Go deeper on NCT02450656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450656.